Kinaset Therapeutics Launches with a $40M Series A Financing to Develop Novel Therapeutics for Respiratory Diseases and an Exclusive Global License Agreement with Vectura Group for KN-002 (VR588), a Novel Anti-Inflammatory

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3g0ovtG
via IFTTT